Buy Omacor capsules 1g capsule 28 pcs
  • Buy Omacor capsules 1g capsule 28 pcs

Omega-3 triglycerides

1330 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Omacor - lipid-lowering drug. Contains polyunsaturated essential fatty acids of the omega-3 class - eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - are irreplaceable (essential) fatty acids (NEFA).

Omacor reduces triglycerides by reducing the concentration of very low density lipoproteins (VLDL), in addition, it actively affects hemostasis, reducing the synthesis of thromboxane A2 and slightly increasing the clotting time of the blood.

Delays the synthesis of triglycerides in the liver (by inhibiting the esterification of EPA and DHA).

An increase in peroxisome beta-oxidation of fatty acids (a decrease in the amount of free fatty acids available for the synthesis of triglycerides) contributes to a decrease in triglyceride levels.

The increase in high-density lipoprotein (HDL) is very small and not constant. It is significantly less than after taking fibrates.

The results of observations (within 3.5 years) of patients taking Omacor at a dose of 1 g / day showed a significant reduction in the combined index, including all-cause mortality, as well as non-fatal myocardial infarction and stroke.


  • secondary prevention of myocardial infarction (in combination with other standard treatment methods: statins, antiaggregatory agents, beta-blockers, ACE inhibitors);
  • hypertriglyceridemia: endogenous hypertriglyceridemia - as a supplement to the diet with its lack of efficacy: type IV (as monotherapy), types IIb / III (in combination with statins - when the triglyceride concentration remains high).


1 capsule contains:

Active substances: Omega-3 ethyl esters 1 g, incl. eicosapentaenoic acid ethyl ester (EPA) 46%, docosahexaenoic acid ethyl ester (DHA) 38%, α-tocopherol.

No customer reviews for the moment.

Write your review

Write your review

Omega-3 triglycerides

Dosage and Administration

The drug is taken orally, during the meal.

For the secondary prevention of myocardial infarction, it is recommended to take 1 capsule per day.

When treating hypertriglyceridemia, the initial dose of Omacor is 2 capsules per day. In the absence of a therapeutic effect, it is possible to increase the dose to 4 capsules per day.

The duration of treatment is set individually.

Patients with impaired renal function dose adjustment is not required.

Adverse reactions

Infectious processes: infrequently - gastroenteritis.

On the part of the immune system: infrequently - increased sensitivity.

Metabolism and nutrition disorders: rarely - hyperglycemia.

From the nervous system: infrequently - dizziness, dysgeusia (taste perversion); rarely - headache.

Vascular disorders: very rarely - lowering blood pressure.

On the part of the respiratory, chest and mediastinal organs: very rarely - dry nose.

From the digestive tract: often - dyspepsia, nausea; infrequently - abdominal pain, gastrointestinal disorders, gastritis, pain in the upper abdomen; very rarely - bleeding from the lower GI tract.

Liver: rarely - liver dysfunction.

On the part of the skin and subcutaneous fat: rarely acne, itchy rashes; very rarely - hives.

In the course of research: there was very rarely an increase in the number of blood leukocytes, blood lactate dehydrogenase. Patients with hypertriglyceridemia reported a moderate increase in transaminases (AST, ALT).

Reports of sporadic side effects.

Metabolism and nutrition disorders: increased insulin requirements (the need to increase the standard dose).

Liver disorders: increased liver enzymes.

Violations of the skin and subcutaneous tissues: rosacea, rash, redness / erythema, urticaria in the chest, neck and shoulders.


The drug should be prescribed with caution in case of marked impaired liver function, while being used with fibrates, with oral anticoagulants, with severe injuries, surgical operations (due to the risk of increased bleeding time), elderly patients (over 70 years of age), and children and adolescents under the age of 18 years (efficacy and safety have not been established).

Drug interactions

With the simultaneous use of Omacor with oral anticoagulants, there is a risk of increased bleeding time.

Appointment of Omacor along with warfarin does not lead to any hemorrhagic complications. However, when combined with Omakor and warfarin, or if Omakor stops treatment, it is necessary to control prothrombin time.

Pregnancy and Lactation

The drug is contraindicated for use during pregnancy and lactation (breastfeeding).

Special instructions

In connection with a moderate increase in bleeding time (when taking a high dose - 4 caps.), Monitoring of patients undergoing anticoagulant therapy is required, and, if necessary, a corresponding dose adjustment of the anticoagulant. Conducting this therapy does not preclude the need for routine control in the treatment of such patients. The increase in bleeding time in patients with an increased risk of hemorrhage (as a result of severe injury, surgery, etc.) should be taken into account. Experience in the study of secondary endogenous hypertriglyceridemia (especially uncontrollable diabetes mellitus) is very limited. There is no clinical experience regarding the treatment of hypertriglyceridemia in combination with fibrates. When you receive Omacor, a moderate increase in the activity of liver transaminases is possible. In patients with impaired liver function (especially when taking a high dose - 4 caps.) Requires regular monitoring of liver function (AST and ALT). Information about the use of the drug Omacor in children, elderly patients older than 70 years or in patients with impaired liver function is not available.In patients with impaired renal function, dose adjustment is not required.


Symptoms: possible side effects and their severity.

Treatment: conduct symptomatic therapy.

  • Active ingredient: Omega-3

Studies and clinical trials of Omega-3 triglycerides (Click to expand)

  1. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides
  2. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides
  3. Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic β-cell response in subjects with primary hypertriglyceridemia
  4. Omega-3 fatty acid concentrate decreased triglycerides in coronary heart disease patients treated with simvastatin
  5. Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation
  6. The HS-Omega-3 Index Is Favorably Associated with Triglycerides and Inflammatory Markers: Data from 100,000 Patients
  8. Regulation of human stearoyl-CoA desaturase by omega-3 and omega-6 fatty acids: Implications for the dietary management of elevated serum triglycerides
  9. AMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients with Very High Triglycerides Without Raising LDL-C: The MARINE Study
  10. P1028 Les acides gras oméga 3 diminuent le risque cardiovasculaire en améliorant le métabolisme des sphingolipides et des triglycérides des VLDL
  11. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
  12. Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia
  13. Variables affecting homogeneous acid catalyst recoverability and reuse after esterification of concentrated omega-9 polyunsaturated fatty acids in vegetable oil triglycerides
  14. Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents
  15. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia
  16. Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients
  17. Short Communication: Effects of Omega-3 Fatty Acids on Triglycerides and High-Density Lipoprotein Subprofiles in HIV-Infected Persons with Hypertriglyceridemia
  18. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia
  19. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol
  20. Successful Treatment of Severe Hypertriglyceridemia with a Formula Diet Rich in Omega–3 Fatty Acids and Medium-Chain Triglycerides
  21. Omega-3 fatty acids for the treatment of elevated triglycerides
  22. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides

8 other products in the same category: